Ernexa Therapeutics appoints Robert J. Spiegel to board of directors
The Cambridge biotech named Spiegel a director effective September 14, 2026, following a recommendation from its Nominating and Corporate Governance Committee.
Ernexa Therapeutics Inc. disclosed in an 8-K filing that on September 14, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directors, the company approved the appointment of Robert J. Spiegel, M.D. to serve as a member of the board, effective immediately.1
Per the filing, Spiegel will serve until his successor is duly elected and qualified, or until his earlier death, resignation, or removal.1
On compensation, the company said Spiegel will be compensated in accordance with the company's Board of Directors Compensation Plan adopted effective August 15, 2026, as described in its Quarterly Report on Form 10-Q for the period ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026.1
The filing also addressed related-party and conflict disclosures, stating there are no arrangements or understandings between Spiegel and any other person pursuant to which he was appointed as a director, and there is no family relationship between Spiegel and any other director or executive officer of the company or any person nominated or chosen by the company to become a director or executive officer.1 It further noted there are no transactions between the company and Spiegel that are reportable pursuant to Item 404(a) of Regulation S-K.1
The 8-K was signed on September 16, 2026, by Sanjeev Luther, Ernexa's President and Chief Executive Officer.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.